Cargando…

Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production

Dendritic cell [DC] vaccines can induce durable clinical responses, at least in a fraction of previously treated, late stage cancer patients. Several preclinical studies suggest that shielding programmed death-ligand 1 [PD-L1] on the DC surface may be an attractive strategy to extend such clinical b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Broos, Katrijn, Lecocq, Quentin, De Keersmaecker, Brenda, Raes, Geert, Corthals, Jurgen, Lion, Eva, Thielemans, Kris, Devoogdt, Nick, Keyaerts, Marleen, Breckpot, Karine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789804/ https://www.ncbi.nlm.nih.gov/pubmed/31394834 http://dx.doi.org/10.3390/vaccines7030085

Ejemplares similares

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
por: Broos, Katrijn, et al.
Publicado: (2019)

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
por: Broos, Katrijn, et al.
Publicado: (2017)

Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
por: Lecocq, Quentin, et al.
Publicado: (2021)

The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
por: Lecocq, Quentin, et al.
Publicado: (2020)

Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
por: Bridoux, Jessica, et al.
Publicado: (2020)

Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade
por: Awad, Robin Maximilian, et al.
Publicado: (2021)

Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019)

Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
por: Lecocq, Quentin, et al.
Publicado: (2019)

Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation
por: Fostier, Karel, et al.
Publicado: (2018)

Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry
por: Chigoho, Dora Mugoli, et al.
Publicado: (2021)

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
por: Versteven, Maarten, et al.
Publicado: (2018)

Phase I Study of [(68)Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)
por: Gondry, Odrade, et al.
Publicado: (2023)

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
por: De Keersmaecker, Brenda, et al.
Publicado: (2020)

Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8(+) T cell and iNKT cell activating mRNA vaccine
por: Ertveldt, Thomas, et al.
Publicado: (2023)

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon
por: Broos, Katrijn, et al.
Publicado: (2016)

Clinical trials with MRNA electroporated dendritic cells for stage III/IV melanoma patients
por: Wilgenhof, Sofie, et al.
Publicado: (2015)

Targeting the tumor microenvironment to enhance antitumor immune responses
por: Van der Jeught, Kevin, et al.
Publicado: (2014)

The role of SMAC mimetics in regulation of tumor cell death and immunity
por: Emeagi, Perpetua U., et al.
Publicado: (2012)

Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
por: Puttemans, Janik, et al.
Publicado: (2020)

Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma
por: Thielemans, Kris, et al.
Publicado: (2014)

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
por: Ertveldt, Thomas, et al.
Publicado: (2022)

Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer
por: Lecocq, Q., et al.
Publicado: (2021)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1(+) Myeloid Dendritic Cells
por: Kalus, Philipp, et al.
Publicado: (2022)

In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4(+) T cells
por: Awad, Robin Maximilian, et al.
Publicado: (2023)

Immunogenicity of targeted lentivectors
por: Goyvaerts, Cleo, et al.
Publicado: (2014)

Characterization of CD8(+) T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
por: Benteyn, Daphné, et al.
Publicado: (2013)

An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8(+) T cells
por: de Mey, Wout, et al.
Publicado: (2023)

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
por: Van Lint, Sandra, et al.
Publicado: (2013)

Immunogenicity Risk Profile of Nanobodies
por: Ackaert, Chloé, et al.
Publicado: (2021)

Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells
por: Dufait, Inès, et al.
Publicado: (2019)

P18-03. Dendritic cell-based immune therapy against HIV-1
por: Gruters, RA, et al.
Publicado: (2009)

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
por: Zeven, Katty, et al.
Publicado: (2023)

RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System
por: De Mey, Wout, et al.
Publicado: (2022)

The antigen‐binding moiety in the driver's seat of CARs
por: Hanssens, Heleen, et al.
Publicado: (2021)

The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
por: Goyvaerts, Cleo, et al.
Publicado: (2018)

Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours
por: Bialkowski, Lukasz, et al.
Publicado: (2016)

Neo-Antigen mRNA Vaccines
por: Esprit, Arthur, et al.
Publicado: (2020)

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
por: Benteyn, Daphné, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1i0kt8qts3lf795k2p0ut0i0im